# Midweek Market Mayhem: Trials, Teases & Turmoil! Newsy: Bud Fox's 3 Controversial Stocks of the Day Published: 2026-05-28T14:01:00.219Z Source: https://newsyai.com/edition/3f78a02a-8ee7-457f-84f7-7f8ca1631255 Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md --- **Quantum Quagmires, ATP Aphrodisiacs & Shipping Shenanigans: SPRC’s Trial Tease, ATPC’s Order Orgy & NCT’s Compliance Cock-Up!** Futures are doing the mid-week mope—Dow futures flat-to-down a hair, Nasdaq futures twitching lower, while crude oil keeps humping near $100+ on geopolitical tease vibes. Microcap madness rules the roost again: low-float levitation, acquisition hype, and fresh dilution dong-drops. Today’s chaos triumvirate? **SPRC** blasting on quantum trial acquisition approval, **ATPC** riding a massive premarket erection on purchase-order hype, and **NCT** surging amid shipping expansion whispers and compliance history. Bulls chasing the rocket; bears screaming “reverse-split rape and cash-burn ahead!” Let’s dissect the dick-measuring contest. ### 1) SciSparc Ltd. (SPRC): “+184% Quantum Sausage” vs “Acquisition Acrobatics & Dilution Doom” **Why it’s loud** **SPRC** rocketed ~184% premarket (tiny mcap, volume exploding) after its subsidiary NeuroThera Labs got conditional TSX Venture Exchange approval to snag ~54% of CliniQuantum, a quantum-based clinical trials innovator. Deal involves issuing 56.6M NeuroThera shares (~$9.46M value, escrowed), with a $0.05 floor on earn-outs and extended close to June 1. Earlier patent filings for depression therapies and NeuroThera’s majority stake push add rocket fuel—but this is classic microcap biotech zero-to-hero with serious execution shadows and compliance scars.[[1]](https://www.stocktitan.net/news/SPRC/) **Bull case (quantum cock rocket)** Quantum clinical trials tailwinds + patent momentum + low-float squeeze + underserved neuro/psychedelic-adjacent markets = $15–25 supernova. Ape the asset annihilation, degens! **Bear case (trial tease & raise rape)** Repeated equity raises, reverse splits, Nasdaq conditional compliance history, and “quantum” hype that’s years from revenue = sub-$2 bust-out. Short the stock before it craters! **My take, first principles (data vs. dilution dump)** Strip the stats: Concrete subsidiary deal + prior patents give real biotech signal and runway, but quantum clinical trials are speculative as hell and funding will likely come via dilution in this environment. **Real pipeline progress with real risk of repeated raises.** Scalp the spunk? **$8–18**, **$12C** quantum sausage—**P$2** compliance cock-up. ### 2) Agape ATP Corporation (ATPC): “+110% Order Orgy” vs “Compliance Catastrophe & Cash Burn Carnage” **Why it’s loud** **ATPC** surged ~110%+ premarket (volume insane) on fresh Irrevocable Corporate Purchase Order (ICPO) momentum and retail frenzy. History includes massive prior swings, Nasdaq minimum bid deficiency notices (compliance deadline July 2026), and microcap volatility. Retail retching the ATP boner while chronic cash burn and governance mess loom large.[[2]](https://www.tradingview.com/symbols/NASDAQ-ATPC/) **Bull case (order orgy fuck-fest)** Purchase order hype + low-float levitation + rebound from oversold lows = $8–15 moonshot. Ride the retail rocket! **Bear case (compliance cock-up & dilution dong-drop)** Ongoing Nasdaq bid-price risks, repeated equity raises, massive cash burn, and history of 90%+ drops = sub-$1 bust-out. Short the stock! **My take, first principles (order signal vs. funding fuckery)** Boil the books: Real purchase-order momentum shows commercial interest, but microcap biotechs/packaged-food plays like this almost always dilute and face delisting threats. **Rebound potential with compliance razor.** Value vulture? **$3–7**, **$5C** order orgy—**P$1** deficiency doom. ### 3) Intercont (Cayman) Limited (NCT): “+113% Shipping Stiffy” vs “Reverse-Split Rape & Expansion Edge” **Why it’s loud** **NCT** jumped ~113% premarket (mcap still micro, volume surging) on momentum from European expansion strategy (FreeNow acquisition whispers) and maritime ESG/onboard pulp tech plays. Company history includes IPO, 25-for-1 reverse split for Nasdaq compliance, and shipping fleet growth bets. Retail frenzy on no-fresh-news surge; bears point to dilution and operational risks.[[3]](https://intellectia.ai/news/monitor/intercont-cayman-ltd-surges-amid-market-weakness) **Bull case (shipping stiffy fuck-fest)** Expansion tailwinds + ESG industrialization hype + low-float squeeze = $10–20 supernova. Ape the asset annihilation! **Bear case (compliance cock-up & dilution dump)** Reverse-split history, ongoing compliance fears, cash burn, and maritime volatility = sub-$1 bust-out. Short the stock! **My take, first principles (expansion edge vs. raise rape)** Core the code: Concrete European push and tech initiatives give real operational signal, but funding and compliance will likely require raises. **Strategic reset with execution edge but dilution danger.** Momentum monkey-business? **$4–10**, **$7C** shipping stiffy—**P$1.50** compliance cock-up. **Tape-Side Tactics (SPRC Quantum Sausage, ATPC Order Orgy & NCT Shipping Stiffy?)** - **SPRC**: **$8–18** quantum sausage; **$12C** trial tingle, **P$2** raise rape. - **ATPC**: **$3–7** order orgy; **$5C** purchase pump, **P$1** deficiency doom. - **NCT**: **$4–10** shipping stiffy; **$7C** expansion erection, **P$1.50** compliance cock-up. Futures foreskin-flay amid crude cock-up and micro-madness. Balls-deep DYOR, NFA, degens duck the dilutions! **Sources** (for tracking every claim above): - Premarket movers & % changes: StockAnalysis.com, Benzinga, CNN Markets (May 28, 2026 data). - SPRC NeuroThera/CliniQuantum approval & patents: StockTitan, company releases (May 2026). - ATPC ICPO & compliance notices: TradingView, Investing.com (May 2026). - NCT expansion strategy & reverse-split history: StockToTrade, company news releases (May 2026). - Volatility & context: Yahoo Finance, MarketWatch (May 28, 2026).